Ionis Prescription drugs CFO sells inventory price $290,989

Elizabeth L. Hougen, Government Vice President, Finance & CFO of Ionis Prescription drugs Inc. (NASDAQ:IONS), just lately executed a number of transactions involving the corporate’s frequent inventory. In keeping with a current SEC submitting, Hougen offered 8,870 shares on January 16 at a weighted common value of $32.806 per share, amounting to a complete of $290,989. This sale was made to cowl tax withholding obligations as a part of the 2011 Fairness Incentive Plan.

Moreover, Hougen acquired 23,887 shares on January 15 by the vesting and launch of shares from Restricted Inventory Unit awards. These transactions replicate ongoing administration actions below Ionis Prescription drugs’ fairness incentive applications. The corporate maintains a robust liquidity place with a present ratio of 8.91, although it reported a loss per share of $2.46 over the past twelve months. InvestingPro subscribers can entry 8 extra key insights and a complete Professional Analysis Report about Ionis Prescription drugs, serving to traders make extra knowledgeable selections.

In different current information, Ionis Prescription drugs has maintained its optimistic rankings from Piper Sandler and Needham following the FDA’s approval of its drug TRYNGOLZA, or olezarsen, for the therapy of familial chylomicronemia syndrome (FCS). The drug, priced at $595,000 per 12 months, is predicted to generate $37 million in U.S. FCS income for the fiscal 12 months 2025, in accordance with Piper Sandler. Ionis plans to transition sufferers from Open-Label Extension (OLE) and Expanded Entry Program (EAP) to the business drug through the first half of 2025.

Moreover, the corporate is awaiting outcomes from pivotal research for the drug’s use in extreme hypertriglyceridemia (sHTG), anticipated within the second half of 2025. Analysts from Needham have indicated the potential of a value discount if the drug additionally receives approval for this broader indication.

In its third quarter 2024 monetary outcomes, Ionis emphasised its non-GAAP financials, reflecting the corporate’s confidence in its operational administration and long-term prospects. These current developments underscore Ionis Prescription drugs’ ongoing strides within the pharmaceutical business, with the FDA approval marking a major milestone within the firm’s transition into a brand new section of business drug distribution.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.